Search for other papers by Yun Cai in
Google Scholar
PubMed
Search for other papers by Jieni Yan in
Google Scholar
PubMed
Search for other papers by Yong Gu in
Google Scholar
PubMed
Search for other papers by Heng Chen in
Google Scholar
PubMed
Search for other papers by Yang Chen in
Google Scholar
PubMed
Search for other papers by Xinyu Xu in
Google Scholar
PubMed
Search for other papers by Mei Zhang in
Google Scholar
PubMed
Search for other papers by Liping Yu in
Google Scholar
PubMed
Search for other papers by Xuqin Zheng in
Google Scholar
PubMed
Search for other papers by Tao Yang in
Google Scholar
PubMed
DM) is the most frequent ( 3 , 4 , 5 ). The phenotype is referred as autoimmune polyendocrine syndrome type II (APS II) when T1DM and AITD occur in the same individual, even sometimes coexist in the same family ( 6 , 7 ). T1DM, as well as AITD
Search for other papers by Zhiyan Yu in
Google Scholar
PubMed
Search for other papers by Yueyue Wu in
Google Scholar
PubMed
Search for other papers by Rui Zhang in
Google Scholar
PubMed
Search for other papers by Yue Li in
Google Scholar
PubMed
Search for other papers by Shufei Zang in
Google Scholar
PubMed
Search for other papers by Jun Liu in
Google Scholar
PubMed
subjects with T2DM were included in this study of whom 654 were male (266 non-NAFLD, 388 NAFLD) and 589 were female (217 non-NAFLD and 372 NAFLD). The clinical and laboratory characteristics are shown in Table 1 . Compared with non-NAFLD patients, those
Search for other papers by Jothydev Kesavadev in
Google Scholar
PubMed
Search for other papers by Pradeep Babu Sadasivan Pillai in
Google Scholar
PubMed
Search for other papers by Arun Shankar in
Google Scholar
PubMed
Search for other papers by Gopika Krishnan in
Google Scholar
PubMed
Search for other papers by Sunitha Jothydev in
Google Scholar
PubMed
shown to reduce HbA1c and delay the need for insulin therapy ( 5 ). Sitagliptin as add-on therapy in T2DM has reported to provide persistent beneficial effects on short-term, intermediate-term and long-term biomarkers of metabolic control, as well as on
Search for other papers by Sweta Budyal in
Google Scholar
PubMed
Search for other papers by Swati Sachin Jadhav in
Google Scholar
PubMed
Search for other papers by Rajeev Kasaliwal in
Google Scholar
PubMed
Search for other papers by Hiren Patt in
Google Scholar
PubMed
Search for other papers by Shruti Khare in
Google Scholar
PubMed
Search for other papers by Vyankatesh Shivane in
Google Scholar
PubMed
Search for other papers by Anurag R Lila in
Google Scholar
PubMed
Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
Search for other papers by Nalini S Shah in
Google Scholar
PubMed
.8% (1.8) 4.1% (5) Our study India 993 1.8 μg/dl (50 nmol/l) Unselected T2DM outpatients 55.1±10.5 (25–87) 0 0/0/0 3.7% (1.8) a Limiting to the cross-sectional cohort alone. b s.e.m . c 2% (4/200 patients) had undergone treatment with definitive evidence
Search for other papers by Peter L Kristensen in
Google Scholar
PubMed
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Ulrik Pedersen-Bjergaard in
Google Scholar
PubMed
Lægerne på Ellemarksvej, Køge, Denmark
Search for other papers by Rikke Due-Andersen in
Google Scholar
PubMed
Department of Cardiology, Herlev-Gentofte University Hospital, Herlev, Denmark
Search for other papers by Thomas Høi-Hansen in
Google Scholar
PubMed
Novo Nordisk A/S, Søborg, Denmark
Search for other papers by Lise Grimmeshave in
Google Scholar
PubMed
Lund University Diabetes Centre, Skåne University Hospital, Malmø, Sweden
Search for other papers by Valeriya Lyssenko in
Google Scholar
PubMed
Finnish Institute for Molecular Medicine (FIMM), Helsinki University, Helsinki, Finland
Search for other papers by Leif Groop in
Google Scholar
PubMed
Department of Biomedical Sciences, NNF Center for Basic Metabolic Research, The Panum Institute, Copenhagen, Denmark
Search for other papers by Jens J Holst in
Google Scholar
PubMed
Department of Endocrinology, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark
Search for other papers by Allan A Vaag in
Google Scholar
PubMed
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Birger Thorsteinsson in
Google Scholar
PubMed
candidate risk genes for type 2 diabetes, the T allele of rs7903146 transcription factor 7-like 2 ( TCF7L2 ) has been shown to confer the hitherto strongest association with type 2 diabetes, with a per allele odds ratio of 1.4 ( 22 , 23 , 24 ). During the
Search for other papers by M Boering in
Google Scholar
PubMed
Isala, Department of Internal Medicine, Zwolle, The Netherlands
Search for other papers by P R van Dijk in
Google Scholar
PubMed
Langerhans Medical Research group, Zwolle, The Netherlands
Search for other papers by S J J Logtenberg in
Google Scholar
PubMed
Department of General Practice, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Search for other papers by K H Groenier in
Google Scholar
PubMed
Search for other papers by B H R Wolffenbuttel in
Google Scholar
PubMed
Search for other papers by R O B Gans in
Google Scholar
PubMed
Langerhans Medical Research group, Zwolle, The Netherlands
Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Search for other papers by N Kleefstra in
Google Scholar
PubMed
Isala, Department of Internal Medicine, Zwolle, The Netherlands
Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Search for other papers by H J G Bilo in
Google Scholar
PubMed
Introduction Among type 1 diabetes mellitus (T1DM) patients, subcutaneous (SC) insulin administration is associated with low portal insulin concentrations and a consequent hepatic underinsulinization ( 1 ). Hepatic underinsulinization has been
Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China
Search for other papers by Lili Liu in
Google Scholar
PubMed
Search for other papers by Zhuo Shao in
Google Scholar
PubMed
Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China
Search for other papers by Ying Xia in
Google Scholar
PubMed
Search for other papers by Jiabi Qin in
Google Scholar
PubMed
Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China
Search for other papers by Yang Xiao in
Google Scholar
PubMed
Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China
Search for other papers by Zhiguang Zhou in
Google Scholar
PubMed
Search for other papers by Zubing Mei in
Google Scholar
PubMed
Introduction Type 1 diabetes mellitus (T1DM), which is caused by the selective destruction of the insulin-producing β cells located in the pancreatic islets of Langerhans, is one of the most common and debilitating autoimmune diseases ( 1
Search for other papers by Giovanni Fanni in
Google Scholar
PubMed
Search for other papers by Petros Katsogiannos in
Google Scholar
PubMed
Search for other papers by Bipasha Nandi Jui in
Google Scholar
PubMed
Search for other papers by Magnus Sundbom in
Google Scholar
PubMed
Search for other papers by Susanne Hetty in
Google Scholar
PubMed
Search for other papers by Maria J Pereira in
Google Scholar
PubMed
Search for other papers by Jan W Eriksson in
Google Scholar
PubMed
Introduction Besides inducing significant and durable weight loss, Roux-en-Y gastric bypass (RYGB) improves glycemic control in insulin-resistant patients and can prevent or reverse type 2 diabetes mellitus (T2DM) ( 1 , 2 , 3 ). This
Search for other papers by C L Bodinham in
Google Scholar
PubMed
Search for other papers by L Smith in
Google Scholar
PubMed
Search for other papers by E L Thomas in
Google Scholar
PubMed
Search for other papers by J D Bell in
Google Scholar
PubMed
Search for other papers by J R Swann in
Google Scholar
PubMed
Search for other papers by A Costabile in
Google Scholar
PubMed
Search for other papers by D Russell-Jones in
Google Scholar
PubMed
Search for other papers by A M Umpleby in
Google Scholar
PubMed
Search for other papers by M D Robertson in
Google Scholar
PubMed
with well-controlled diabetes (mean HbA1c, 46.6 mmol/mol and target UK level for T2DM, 48 mmol/mol), taking oral hypoglycemics, HAM-RS2 intake resulted in a significant improvement in the meal glucose handling ( Fig. 1 ) without a change in medication
Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Yutong Zou in
Google Scholar
PubMed
Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Lijun Zhao in
Google Scholar
PubMed
Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Junlin Zhang in
Google Scholar
PubMed
Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Yiting Wang in
Google Scholar
PubMed
Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Yucheng Wu in
Google Scholar
PubMed
Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Honghong Ren in
Google Scholar
PubMed
Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Tingli Wang in
Google Scholar
PubMed
Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Rui Zhang in
Google Scholar
PubMed
Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Jiali Wang in
Google Scholar
PubMed
Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Yuancheng Zhao in
Google Scholar
PubMed
Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Chunmei Qin in
Google Scholar
PubMed
Search for other papers by Huan Xu in
Google Scholar
PubMed
Search for other papers by Lin Li in
Google Scholar
PubMed
Search for other papers by Zhonglin Chai in
Google Scholar
PubMed
Search for other papers by Mark E Cooper in
Google Scholar
PubMed
Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Nanwei Tong in
Google Scholar
PubMed
Laboratory of Diabetic Kidney Disease, Centre of Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, Sichuan, China
Search for other papers by Fang Liu in
Google Scholar
PubMed
and DN patients who had undergone percutaneous renal biopsy between January 2008 and July 2019 and had at least 1-year follow-up at the West China Hospital of Sichuan University were enrolled for the longitudinal observational study. T2DM was diagnosed